نوع مقاله: مقاله کوتاه

نویسندگان

1 گروه بیوتکنولوژی پزشکی، دانشکده فناوری‌های نوین، دانشگاه علوم پزشکی شهرکرد، شهرکرد، ایران

2 مرکز تحقیقات سلولی و مولکولی، پژوهشکده علوم پایه سلامت، دانشگاه علوم پزشکی شهرکرد، شهرکرد، ایران

چکیده

مقدمه: بیوفارماسیوتیکال به فراورده‌های پروتئینی یا اسیدنوکلئیکی گفته می‌شود که برای درمان یا تشخیص استفاده می‌شوند.مواد و روش: مقاله حاضر باجستجو در پایگاه‌های اصیل اطلاعاتی منجمله وبسایت شرکت‌های معتبر دارویی، پایگاه‌های اطلاعاتی بین‌المللی Web of Science، Springer، Scopus، Pubmed و موتور جستجوگر Google Scholar نگارش شده است.یافته‌ها: گزارش سالیانه شرکت‌های داروسازی که اخیراً منتشر گردیده است بسیار جذاب می­باشد. عایدی حاصل از فروش کل فراورده‌های دارویی در سال 2016 با رشد مثبت 9/4 درصدی حدود 780 میلیارد دلار آمریکا تخمین زده شده است. شرکت جانسون-جانسون با 72 میلیارد دلار رتبه نخست درامد در بین تمام شرکت‌های دارویی جهان و ایالات متحده را به خود اختصاص داد. علیرغم محدودیت‌های متعدد که در سال‌های اخیر برای شرکت‌های دارویی وضع گردید رشد میانگین 3/6 درصد در سال تحقق یافت و پیش­بینی می‌شود فروش کل فراورده‌های دارویی در سال 2022 به 3/1 تریلیون دلار برسد. در سال 2016 فراورده‌های بیوفارماسیوتیکال با ارزش 197 میلیارد دلار 24% درصد از کل ارزش دارویی جهان را به خود اختصاص دادند. در این بین آنتی‌بادی‌ها با ارزش حدودی 82 میلیارد دلار به تنهایی نیمی از بازار بیوفارماسیوتیکال‌ها را پوشش دادند.نتیجه‌گیری: به نظر می‌رسد که شرکت‌های بیوفارماسیوتیکال با رشد بی سابقه‌ای بتوانند 30 درصد از کل ارزش اقتصادی فراورده‌های دارویی سال 2022 را به خود اختصاص دهند. داروهای ضدسرطان به عنوان بزرگترین دستجات دارویی با رشد 5/12 درصدی به ارزش 190 میلیارد در سال 2022 دست خواهند یافت. بنابراین دور از انتظار نیست که شرکت رُش، عالی‌رتبه‌ترین شرکت بیوفارماسیوتیکال جهان با خلاقانه‌ترین پروژه‌های ضدسرطانی شناخته شود. به نظر می‌رسد شرکت رُش که همکنون بزرگترین شرکت بیوفارماسیوتیکال جهان محسوب می‌شود، در سال 2022 با نوارتیس برای تصاحب جایگاه اول شرکت‌های دارویی رقابت کند.

کلیدواژه‌ها

عنوان مقاله [English]

New Economics of the Biopharmaceutical Industries and Job Opportunities

نویسندگان [English]

  • Fatemeh Elahian 1
  • Seyed abbas Mirzaei 1 2

1 Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran

2 Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran

چکیده [English]

Background: Biopharmaceutical is either protein or nucleic acid based drug that is approved for therapeutic, diagnostic, or disease prevention applications.
Methods: This study was conducted by a careful bibliography and search through original pharmaceutical company websites such as Web of Sciences, Springer, Scopus, Pubmed, and Google scholar.
Results: The annual pharmaceutical company reporting season started a few months ago and brought exciting full-year events. The global market value was estimated
US$780 billion in 2016, representing an accelerating trend with more than 4.9% growth for the industry. Johnson & Johnson was the first ranked company both globally and in the US with a market around $72 billion in 2016. Despite the growing challenges posed to the pharmaceutical companies, they are estimated to grow at an average rate of 6.3% per year, reaching $1.3 trillion by 2022. In 2016, biopharmaceutical products represented sales of $197 billion appropriated 24% of the global market. Antibodies alone had sales of $82 billion, near to half of the biopharmaceutical market.
Conclusion: Results from the health care world represent that the biopharmaceutical industries are spectacularly occupying the pharmaceutical market and they are expected to continue to grow up to 30% of global drug market in 2022. Oncology agents are recognized as the largest market value all around the world with a predicted annual growth of 12.5%, reaching approximately $190 billion in 2022. Therefore, it is not surprising to recognize Roche as the top ranking biopharmaceutical pipeline with innovative oncology projects in the industry. Roche is expected to be the best biopharmaceutical selling company, competing Novartis for the first spot in 2022.

کلیدواژه‌ها [English]

  • Pharmaceutical Biotechnology
  • Biologic agents
  • Economics
  • Protein

  1. M. Mansouri, S.A. Mirzaei, H. Lage, S.S. Mousavi, F. Elahian, The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells, Biochimie, 99 (2014) 71-76.
  2. A. Kumar, K. Juluru, P.K. Thimmaraju, J. Reddy, A. Patil, Pharmaceutical market access in emerging markets: concepts, components, and future, J Mark Access Health Policy, 2 (2014).
  3. G. Walsh, Pharmaceutical Biotechnology, John Wiley and Sons2007.
  4. V. Afshari, F. Elahian, Y. Ayari, A. Yazdinezhad, S.A. Mirzaei, Diversity and ecotypic variation in the antioxidant and antigenotoxic effects of Thymus kotschyanus Boiss & Hohen, Flav Frag J, 31 (2016) 429-437.
  5. R.M. Twyman, S. Schillberg, R. Fischer, Transgenic plants in the biopharmaceutical market, Expert Opin Emerg Drugs, 10 (2005) 185-218.
  6. S.A. Mirzaei, N. Gholamian Dehkordi, M. Ghamghami, A.H. Amiri, E. Dalir Abdolahinia, F. Elahian, ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells, Toxicol Appl Pharmacol, 337 (2017) 22-29.
  7. F. Elahian, B. Moghimi, F. Dinmohammadi, M. Ghamghami, M. Hamidi, S.A. Mirzaei, The anticancer agent prodigiosin is not a multidrug resistance protein substrate, DNA Cell Biol, 32 (2013) 90-97.
  8. F. Elahian, S. Reiisi, A. Shahidi, S.A. Mirzaei, High-throughput bioaccumulation, biotransformation, and production of silver and selenium nanoparticles using genetically engineered Pichia pastoris, Nanomedicine, (2016).
  9. R. Dixit, F.S. David, Market watch: Trends in pharmaceutical company R&D spending: 2005-2015, Nat Rev Drug Discov, 16 (2017) 376.
  10. E.L. Tobinick, The value of drug repositioning in the current pharmaceutical market, Drug News Perspect, 22 (2009) 119-125.
  11. S.A. Regnier, D.B. Ridley, Market watch: Forecasting market share in the US pharmaceutical market, Nat Rev Drug Discov, 14 (2015) 594-595.
  12. A. Fugh-Berman, How basic scientists help the pharmaceutical industry market drugs, PLoS Biol, 11 (2013) e1001716.
  13. S. Sendyona, I. Odeyemi, K. Maman, Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings, J Mark Access Health Policy, 4 (2016).
  14. V.M. Pashkov, I.A. Golovanova, A.A. Olefir, The impact of the legal regime of intellectual property protection in the pharmaceutical market, Wiad Lek, 69 (2016) 582-586.
  15. S. Kogel, E. Walter, Price Comparison in the European Pharmaceutical Market, Value Health, 17 (2014) A406-407.
  16. E. Moorkens, N. Meuwissen, I. Huys, P. Declerck, A.G. Vulto, S. Simoens, The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape, Front Pharmacol, 8 (2017) 314.
  17. V. Prasad, S. Mailankody, Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval, JAMA Intern Med, 177 (2017) 1569-1575.
  18. V. Prasad, K. De Jesus, S. Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions, Nat Rev Clin Oncol, 14 (2017) 381-390.
  19. C.V. Dave, A.S. Kesselheim, E.R. Fox, P. Qiu, A. Hartzema, High Generic Drug Prices and Market Competition: A Retrospective Cohort Study, Ann Intern Med, 167 (2017) 145-151.
  20. U. Storz, Of patents and patent disputes: The TNFalpha patent files. Part 1: Humira, Hum Antibodies, 25 (2017) 1-16.
  21. R. Likic, I. Simic, V. Erdeljic Turk, K. Makar-Ausperger, M. Radacic-Aumiler, I. Cegec, D. Juricic Nahal, I. Kraljickovic, Outlook For Biosimilar Molecules Entering Croatian Pharmaceutical Market In The Period From 2016 To 2020, Clin Ther, 38 (2016) e16.
  22. S.K. Finston, N.S. Davey, E. Dave, V. Ravichandran, S.R. Davey, R.S. Dave, Mayo, Myriad, America Invents Act and BPCIA: how has the United States biopharmaceutical market been affected?, Pharm Pat Anal, 5 (2016) 159-167.
  23. E. Tuna, G. Kockaya, Changes In The Prices Of Reference Biotechnology Products By The Penetration Of Biosimilars Into The Turkish Pharmaceutical Market, Value Health, 18 (2015) A535.
  24. N. Tahmasebi, A. Kebriaeezadeh, Evaluation of factors affecting prescribing behaviors, in iran pharmaceutical market by econometric methods, Iran J Pharm Res, 14 (2015) 651-656.
  25. K. Simon, S.L. Worthy, M.C. Barnes, B. Tarbell, Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety, Ther Adv Drug Saf, 6 (2015) 67-79.
  26. M. Davari, F. Ashrafi, M. Maracy, A. Aslani, M. Tabatabaei, Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market, Int J Prev Med, 6 (2015) 63.
  27. A.S. Kesselheim, N.K. Choudhry, The international pharmaceutical market as a source of low-cost prescription drugs for U.S. patients, Ann Intern Med, 148 (2008) 614-619.
  28. A. Baudouin, E. Fargier, A. Cerruti, A. Dubromel, N. Vantard, F. Ranchon, V. Schwiertz, G. Salles, P.J. Souquet, L. Thomas, F. Berard, S. Nancey, G. Freyer, V. Trillet-Lenoir, C. Rioufol, Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital, Bull Cancer, 104 (2017) 538-551.
  29. K. Nawaz, R.M. Webster, The non-small-cell lung cancer drug market, Nat Rev Drug Discov, 15 (2016) 229-230.
  30. D.H. Howard, P.B. Bach, E.R. Berndt, R.M. Conti, Pricing in the Market for Anticancer Drugs, J Econ Perspect, 29 (2015) 139-162.
  31. Pharmaceutical companies' homepage including: Abbott Laboratories (http://www.abbott.com); AbbVie Inc. (ABBV, https://www.abbvie.com); Alexion Pharmaceuticals (ALXN, http://www.alxn.com); Allergan (AGN, http://www.allergan.com); Amgen Inc (AMGN, http://www.Amgen.com); Astellas Pharma (TYO, http://www.astellas.com); AstraZeneca Pharmaceuticals (AZN, http://www.astrazeneca-us.com); Baxter (BAX, http://www.Baxter.com); Bayer (BAYN, http://www.bayer.com); Biogen Idec (BIIB, http://www.BiogenIdec.com); Boehringer Ingelheim Pharmaceuticals, Inc. (GmBH, http://www.boehringer-ingelheim.com); Bristol-Myers Squibb (BMY, http://www.bms.com); Celgene Corporation (CELG, https://www.celgene.com); Commonwealth Serum Laboratories Limited (CSL, http://www.csl.com.au); Eli Lilly (LLY, http://www.lilly.com); Genzyme (GENZ, http://www.genzyme.com); Gilead Sciences Inc (GILD, http://www.gilead.com); GlaxoSmithKline (GSK, http://www.gsk.com); Hoffmann-La Roche Ltd (ROG, http://www.roche.com); Johnson & Johnson (JNJ, http://www.JNJ.com); Merck & Co Inc (MRK, http://www.Merck.com); Mylan, Inc. (MYL, http://www.Mylan.com); Novartis Pharmaceuticals (NVS, http://www.novartis.com); Novo Nordisk (NVO, http://www.novonordisk.com); Organon (OGA, http://www.organon.com); Pfizer Inc. (PFE, http://www.pfizer.com); Sanofi (SAN, http://www.sanofi.com).
  32. M. Mohseni, H.A. Gorji, B. Ahadinezhad, O. Khosravizadeh, M.S. Keykaleh, A. Moosavi, B. Mohtashamzadeh, The structure of the pharmaceutical market in Iran using concentration indices, Electron Physician, 9 (2017) 4251-4254.
  33. A.M. Cheraghali, Trends in Iran Pharmaceutical Market, Iran J Pharm Res, 16 (2017) 1-7.